Acquisition by Karabelas Argeris N of 10000 shares of Regenxbio at 3.76 subject to Rule 16b-3

RGNX Stock  USD 9.59  0.41  4.47%   
Slightly above 68 percent of all Regenxbio's investors are curious in acquiring. The analysis of the overall investor sentiment regarding Regenxbio suggests that a large number of traders are confidant. Regenxbio's investing sentiment can be driven by a variety of factors including economic data, Regenxbio's earnings reports, geopolitical events, and overall market trends.
  
Filed transaction by Regenxbio Director. Grant, award or other acquisition pursuant to Rule 16b-3

Read at macroaxis.com
Acquisition of 10000 common stock at 3.76 of Regenxbio by Karabelas Argeris N on 3rd of July 2024. This event was filed by Regenxbio with SEC on 2024-07-01. Statement of changes in beneficial ownership - SEC Form 4

Cash Flow Correlation

Regenxbio's cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Regenxbio's relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.
Click cells to compare fundamentals

Regenxbio Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Regenxbio can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Regenxbio Fundamental Analysis

We analyze Regenxbio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Regenxbio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Regenxbio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Working Capital

Working Capital Comparative Analysis

Regenxbio is currently under evaluation in working capital category among its peers. Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .

Regenxbio Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Regenxbio stock to make a market-neutral strategy. Peer analysis of Regenxbio could also be used in its relative valuation, which is a method of valuing Regenxbio by comparing valuation metrics with similar companies.

Peers

Regenxbio Related Equities

REPLReplimune   35.11   
0%
100.0%
PTGXProtagonist Therapeutics   11.55   
0%
32.0%
RCKTRocket Pharmaceuticals   10.32   
0%
29.0%
ANTXAN2 Therapeutics   8.94   
0%
25.0%
MIRMMirum Pharmaceuticals   2.87   
0%
8.0%
DAWNDay One   2.85   
0%
8.0%
GLUEMonte Rosa   1.68   
0%
4.0%
RNAAvidity Biosciences   1.62   
0%
4.0%
STOKStoke Therapeutics   1.42   
0%
4.0%
PLRXPliant Therapeutics   1.01   
0%
2.0%
IMCRImmunocore Holdings   0.50   
0%
1.0%
RVMDRevolution Medicines   0.05   
1.0%
0%
QUREUniqure NV   1.20   
3.0%
0%
KZRKezar Life   1.57   
4.0%
0%
CRNXCrinetics Pharmaceuticals   1.70   
4.0%
0%
FDMT4D Molecular   2.50   
7.0%
0%
PASGPassage Bio   5.56   
15.0%
0%

Additional Tools for Regenxbio Stock Analysis

When running Regenxbio's price analysis, check to measure Regenxbio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regenxbio is operating at the current time. Most of Regenxbio's value examination focuses on studying past and present price action to predict the probability of Regenxbio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regenxbio's price. Additionally, you may evaluate how the addition of Regenxbio to your portfolios can decrease your overall portfolio volatility.